Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest
Display:
?
Drug:  fulvestrant
Find trials that include:  Any drugs shown
Results 1-19 of 19 for your search:
Start Over
A Phase III Study of BKM120 With Fulvestrant in Patients With HR+,HER2-, AI Treated, Locally Advanced or Metastatic Breast Cancer Who Progressed on or After mTORi
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: CBKM120F2303, NCI-2013-00017, 2012-002571-34, NCT01633060
Fulvestrant and/or Anastrozole in Treating Postmenopausal Patients with Stage II-III Breast Cancer Undergoing Surgery
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over
Trial IDs: A011106, NCI-2013-01340, NCT01953588
Study of Efficacy and Safety of LEE011 in Men and Postmenopausal Women With Advanced Breast Cancer.
Status: Active
Phase: Phase III
Type: Treatment
Age: 18 and over, postmenopausal
Trial IDs: CLEE011F2301, NCI-2015-01088, NCT02422615
Study Assessing the Efficacy and Safety of Alpelisib Plus Fulvestrant in Men and Postmenopausal Women With Advanced Breast Cancer Which Progressed on or After Aromatase Inhibitor Treatment.
Status: Active
Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over, postmenopausal if female
Trial IDs: CBYL719C2301, NCI-2015-01171, 2015-000340-42, NCT02437318
Safety and Efficacy Study of MLN0128 in Combination With Exemestane or Fulvestrant in Postmenopausal Women With ER/PR+ Metastatic Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: C31001, NCI-2014-00386, NCT02049957
Study of LEE011 With Fulvestrant and BYL719 or BKM120 in Advanced Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: CLEE011X2108, NCI-2014-01570, NCT02088684
Study of AZD2014 and Palbociclib in Patients With Estrogen Receptor Positive (ER+) Metastatic Breast Cancer
Status: Active
Phase: Phase II, Phase I
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: D2270C00020, NCI-2016-00558, BRE 253, NCT02599714
Anastrozole With or Without Fulvestrant in Treating Postmenopausal Patients With Hormone Receptor Positive Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: H-20431, NCI-2012-00645, NCT00570323
Fulvestrant with or without Ganetespib in Treating Patients with Hormone-Receptor Positive, Advanced or Metastatic Breast Cancer That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 11-477, NCI-2012-00995, F8151631, NCT01560416
Everolimus and Hormone Therapy in Treating Patients with Advanced Hormone Receptor Positive Breast Cancer That Has Progressed or Recurred on Everolimus and Exemestane Therapy
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 19 and over
Trial IDs: WINSHIP2563-13, NCI-2014-02092, IRB00071229, NCT02269670
Radium Ra 223 Dichloride, Hormone Therapy, and Denosumab in Treating Patients with Hormone-Positive, Bone-Dominant Metastatic Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 2014-0508, NCI-2015-00508, NCT02366130
Palbociclib in Combination with Fulvestrant or Tamoxifen Citrate in Treating Patients with Locally Advanced or Metastatic Hormone Receptor Positive Breast Cancer
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: 147522, NCI-2015-01791, CC#147522, TBCRC035, NCT02384239
A Study of GDC-0810 Versus Fulvestrant in Women With Advanced or Metastatic Breast Cancer Resistant to Aromatase Inhibitor Therapy (HydranGea)
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: GO29689, NCI-2015-02287, NCT02569801
PK Study of Pre-Surgical Intramuscular and Intraductal Fulvestrant in Women With Invasive Breast Cancer or DCIS Undergoing Mastectomy
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 18 and over
Trial IDs: ATOS-2015-007, NCI-2016-00299, NCT02540330
A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer
Status: Active
Phase: Phase II
Type: Treatment
Age: 18 and over
Trial IDs: 15804, NCI-2016-00389, 2015-003400-24, I3Y-MC-JPBZ, NCT02675231
Fulvestrant and Palbociclib in Treating Older Patients with Hormone Responsive Breast Cancer That Cannot Be Removed by Surgery
Status: Active
Phase: Phase II
Type: Biomarker/Laboratory analysis, Treatment
Age: 70 and over
Trial IDs: OSU-15266, NCI-2016-00146, 2016C0015, NCT02760030
Start Over